Citations

Showing 10 of 108104 citations.

A randomized, open-label, phase 2 study of emibetuzumab plus erlotinib (LY+E) and emibetuzumab monotherapy (LY) in patients with acquired resistance to erlotinib and MET diagnostic positive (MET Dx+) metastatic NSCLC.
Camidge, D. Ross , Demedts, Ingel , Grosch, Heidrun, Mercurio, Jean-Pierre Di , Molina, Julian R. , Bepler, Gerold , Lewanski, C., Wijayawardana, Sameera R. , Wang, Xuejing Aimee , Morán, Teresa , Mileham, Kathryn Finch , Juan, Óscar , Goldman, Jonathan W. , Park, Keunchil , Wallin, Johan Erik , Wacheck, Volker , Smit, Egbert F

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 9070-9070

10.1200/jco.2016.34.15_suppl.9070 Get It

Pembrolizumab vs docetaxel for previously treated advanced NSCLC with a PD-L1 tumor proportion score (TPS) 1%-49%: Results from KEYNOTE-010.
Molina, Julian R. , Kim, Joo-Hang , Arvis, Catherine Dubos, Ahn, Myung‐Ju , Fidler, Mary J. , Gubens, Matthew A. , Castro, Gilberto de , Shentu, Yue , Im, Ellie, Lubiniecki, Gregory M., Baas, Paul, Garon, Edward B. , Herbst, Roy S. , Kim, Dong‐Wan , Felip, Enriqueta , Perez‐Gracia, José Luis , Han, Ji-Youn , Majem, Margarita , Garrido, Marcelo , Baas, Paul

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 9024-9024

10.1200/jco.2016.34.15_suppl.9024 Get It

Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.
Hamid, Omid , Hwu, Wen‐Jen , Gangadhar, Tara C., Dronca, Roxana , Patnaik, Amita , Zarour, Hassane M. , Li, Xiaoyun , Ebbinghaus, Scot, Hodi, F. Stephen , Robert, Caroline , Ribas, Antoni , Daud, Adil , Wolchok, Jedd D. , Joshua, Anthony M. , Weber, Jeffrey S. , Joseph, Richard W. , Kefford, Richard , Hersey, Peter , Diede, Scott J.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 9503-9503

10.1200/jco.2016.34.15_suppl.9503 Get It

A phase 1/2 study to evaluate safety and efficacy of nivolumab plus brentuximab vedotin in patients with CD30-expressing relapsed/refractory non-Hodgkin lymphomas (NHLs).
Armand, Philippe , Shustov, Andrei R., Moskowitz, Alison J. , Josephson, Neil C. , Salles, Gilles , Masood, Aisha, Ansell, Stephen M. , Salles, Gilles A , Brody, Joshua , Barr, Paul M. , Kline, Justin Paul , Savage, Kerry J. , Kuruvilla, John , Zinzani, Pier Luigi

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: TPS7576-TPS7576

10.1200/jco.2016.34.15_suppl.tps7576 Get It

Association of vitamin D insufficiency with inferior prognosis in follicular lymphoma.
Tracy, Sean , Ansell, Stephen M. , Nowakowski, Grzegorz S. , Thompson, Carrie A. , Inwards, David J. , Johnston, Patrick B. , Micallef, Ivana N. , Allmer, Cristine, Macon, William R. , Maurer, Matthew J. , Witzig, Thomas E. , Drake, Matthew T. , Weiner, George J. , Slager, Susan L. , Habermann, Thomas M. , Link, Brian K. , Cerhan, James R.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: e19067-e19067

10.1200/jco.2016.34.15_suppl.e19067 Get It

The impact of novel induction regimens on transplant outcome in newly diagnosed multiple myeloma after controlling for high-risk FISH cytogenetics.
Muchtar, Eli , Kumar, Shaji , Hayman, Suzanne R. , Kapoor, Prashant , Lacy, Martha Q. , Muchtar, E , Chakraborty, Rajshekhar , Buadi, Francis K. , Dingli, David , Dispenzieri, Angela , Hogan, William J. , Leung, Nelson , Gertz, Morie A.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 8033-8033

10.1200/jco.2016.34.15_suppl.8033 Get It

Clinical utility of the revised international staging system (RISS) in newly diagnosed multiple myeloma.
Tandon, Nidhi , Lacy, Martha Q. , Hayman, Suzanne R. , Kapoor, Prashant , Hwa, Yi L. , Fonder, Amie , Hobbs, Miriam, Zeldenrust, Steven R., Lust, John A., Kumar, Shaji , Rajkumar, S. Vincent , Dispenzieri, Angela , Buadi, Francis K. , Gertz, Morie A. , Leung, Nelson , Go, Ronald S. , Dingli, David , Lin, Yi , Gonsalves, Wilson I.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 8017-8017

10.1200/jco.2016.34.15_suppl.8017 Get It

Evolving changes in M-protein (M), quantitative involved immunoglobulin (Ig), and hemoglobin (Hb) to identify patients (pts) with ultra high-risk smoldering multiple myeloma (UHR-SMM).
Ravi, Praful , Kumar, Shaji , Larsen, Jeremy T. , Lacy, Martha Q. , Kapoor, Prashant , Lust, John A., Kyle, Robert A. , Gonsalves, Wilson I. , Buadi, Francis K. , Go, Ronald S. , Dispenzieri, Angela , Gertz, Morie A. , Rajkumar, S. Vincent

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 8004-8004

10.1200/jco.2016.34.15_suppl.8004 Get It

Phase 1/2 trial of ixazomib, cyclophosphamide, and dexamethasone for newly diagnosed multiple myeloma (NDMM).
Lacy, Martha Q. , LaPlant, Betsy, Halvorson, Alese E. , Kapoor, Prashant , Hwa, Yi L. , Fonder, Amie , Hayman, Suzanne R. , Stewart, A. Keith, Kumar, Shaji , Bergsagel, P. Leif , Buadi, Francis K. , Leung, Nelson , Go, Ronald S. , Dingli, David , Gertz, Morie A. , Lin, Yi , Dispenzieri, Angela , Fonseca, Rafaël , Mıkhael, Joseph , Rajkumar, S. Vincent

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 8002-8002

10.1200/jco.2016.34.15_suppl.8002 Get It